Business Context and Reporting Period
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) filed a Form 6-K on December 30, 2025, reporting unaudited financial results for the six months ended June 30, 2025. The Company, an IP portfolio holder, owns 100% of The Social Proxy Ltd., a web data company. The reporting period is significantly impacted by a comprehensive re-evaluation of assets following disputes with former shareholders of The Social Proxy and the resignation of its key executives.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenues | $517,000 | $0 |
| Cost of Services | $(2,774,000) | $0 |
| Operating Loss | $(7,606,000) | $(596,000) |
| Net Loss | $(5,500,000) | $(219,000) |
| Cash and Cash Equivalents (as of June 30, 2025) | $150,000 | $371,000 (as of Dec 31, 2024) |
| Marketable Securities (as of June 30, 2025) | $109,000 | $772,000 (as of Dec 31, 2024) |
| Total Assets (as of June 30, 2025) | $714,000 | $8,550,000 (as of Dec 31, 2024) |
| Total Liabilities (as of June 30, 2025) | $761,000 | $2,207,000 (as of Dec 31, 2024) |
| Loans and Credit (as of June 30, 2025) | $86,000 | $138,000 (as of Dec 31, 2024) |
Material Changes vs. Prior Period
- Asset Impairment: The Company recorded a full impairment of goodwill and intangible assets related to The Social Proxy, totaling $3,193,000 in impairment expenses. This was driven by disputes with former shareholders and executive resignations.
- Revenue Recognition: Revenue of $517,000 was recognized for the first time due to the consolidation of The Social Proxy results following its acquisition on August 14, 2024. The prior period had no revenue.
- Expense Increases: Cost of services increased by $2,774,000 and Sales and Marketing expenses by $1,066,000, primarily due to the consolidation of The Social Proxy and the aforementioned impairment charges.
- Warrant Liability Reduction: Warrant liabilities decreased significantly. Net warrants dropped from $1,279,000 to $37,000, and long-term warrants were reduced to $0. This resulted in a finance income of $1,887,000 due to the cancellation and fair value decrease of these instruments.
- Liquidity Decline: Combined cash and marketable securities decreased by approximately $880,000 from December 31, 2024, attributed to operating expenses and the sale of InterCure Ltd. shares.
Outlook, Risks, and Management Commentary
Management has conducted a comprehensive re-evaluation of assets and liabilities due to ongoing significant disputes with former shareholders of The Social Proxy. Following the resignation of The Social Proxy's key executives on December 12, 2025, the Company decided to write down the subsidiary's asset valuation almost entirely.
Risks and Contingencies:
- Legal Disputes: While no provision for litigation costs is currently recognized, the Company is actively considering ongoing disputes with former shareholders of The Social Proxy.
- Data Availability: The Company notes that no further data has been provided by The Social Proxy subsidiary after June 30, 2025, limiting visibility into post-period performance.
- Forward-Looking Statements: The filing includes standard cautionary language regarding risks in the digital assets sector and the volatility of securities values.
Investor Verification Checklist
- Verify the status and potential financial impact of the ongoing disputes with former shareholders of The Social Proxy.
- Confirm the Company's ability to continue operations given the low cash balance of $150,000 and the cessation of data flow from its primary subsidiary.
- Review the details of the exclusive sublicense agreement with Biossil Inc. and the derecognition of the associated intangible asset.
- Assess the sustainability of the Company's business model following the full impairment of The Social Proxy's goodwill and intangible assets.